: Orange Book Blog: At the Intersection of Patent Law and FDA Law
ACI "Pharma/Biotech IP Due Diligence" Conference, New York, January 30-31
By Aaron Barkoff
American Conference Institute will hold its fifth annual "Pharma/Biotech IP Due Diligence" conference January 30-31 in New York. ACI describes this conference as the "complete guide for M&As, licensing and other collaborations."
The agenda includes several talks that sound especially interesting, including:
"Factoring Patent Reform, PTO Rulemaking and New Case Law Into Your Due Diligence Analysis"
"Managing Due Diligence When Dealing with Industry/University Collaborations and Licenses"
"Evaluating the Scope, Validity, and Enforceability of the Target's Patents"
"Freedom to Operate: Ensuring the Purchaser/Licensee Has the Right to Commercialize the IP at Issue"
"FDA Regulation of Small Molecule Drugs and Biologics: Understanding How This Affects the Diligence Review"
In addition, ACI is offering an optional master class on February 1, entitled "Drafting an Effective Due Diligence Report."
ACI Pharma/Biotech IP Due Diligence Conference American Conference Institute (ACI) will be holding its 6th National Conference on Pharma/Biotech IP Due Diligence from January 28-29, 2009 in New York. The conference will allow attendees to: ? Define the company's business goals before you begin a due diligence review;? Navigate the dynamic labyrinth of cases that can impact the company's IP rights;? Ensure a data trail that tracks the disclosure of appropriate information;? Gauge the effect of the patents in question on the company's freedom to operate;? Cultivate a sufficient search strategy to enhance your knowledge base of the IP's strengths, weaknesses, and potential;? Evaluate the benefits,...
C5 Pharma/Biotech IP Due Diligence Conference C5 (UK) will be holding its Pharma/Biotech IP Due Diligence conference on October 28-29, 2008 in Amsterdam, Netherlands. The conference will offer presentations on the following topics: ? Current trends in patent reform and how they impact your due diligence; ? Assessing the level of due diligence required and special considerations for complex multi-jurisdictional and multi-party transactions; ? A practical look at drafting the checklist and due diligence team selection; ? Essential valuation issues affecting the diligence review; ? Finding the target's prior licensing, contractual, and third party obligations; ? Freedom to operate: Ensuring the purchaser/licensee has right to commercialize...
Biotech/Pharma Lobbying Scoreboard - Part II By Donald Zuhn -- For the past few months, Patent Docs has been following and reporting on biotech and pharma lobbying efforts. Our interest in this topic stems from the push by Congress over the past year to pass patent reform and follow-on biologics legislation, and corresponding efforts by corporations and organizations during that time to lobby on this legislation...
USPTO's Bruce Kisliuk Addresses ACI Conference By Donald Zuhn -- At last week's American Conference Institute (ACI) Pharma/Biotech Patent Claim Drafting and Prosecution conference, Bruce Kisliuk, the Director of the U.S. Patent and Trademark Office's Technology Center 1600, gave an interesting address in which he touched on a number of topics, and then opened the floor...